Share
U.K. Atrial Fibrillation Devices Market: Segmented: By Device Type (Diagnostic and Monitoring Devices and Therapeutic and Surgical Devices), By Disorder Type (Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation, Permanent Atrial Fibrillation, Others Atrial Fibrillation ), By End-User (Hospitals, Cardiac Labs, Ambulatory Surgical Centers, Others), And Region - Analysis of Market Size, Share & Trends For 2019-2021 And Forecasts To 2031
U.K. Atrial Fibrillation Devices Market to surpass USD 2.063.9 million by 2031 from USD 706.1 million in 2021 at a CAGR of 11.3% in the coming years, i.e., 2021-2031.
Atrial fibrillation (AF) is a type of cardiac arrhythmia which is caused by irregular electrical activities in the atria. It may occur with no symptoms but the most common ones associated with it are palpitations, fainting, congestive chest pain, or failure of the heart. The confirmation for AF is obtained by an electrocardiogram which exhibits an absence of the P wave and an irregular rate of ventricular contractions. These irregularities in the regular cardio-electric impulses of the sino-atrial node are the result of interference from chaotic electric impulses generated from the roots of pulmonary veins consequently leading to the conduction of an irregular heartbeat.
In the U.K. many companies have increased their investment in research and development to innovate the existing AF devices and integrate AI-enabled solutions. R&D in atrial fibrillation is expected to offer lucrative growth opportunities for players in the U.K. atrial fibrillation market.
U.K. Atrial Fibrillation Devices Market: SegmentsBased on Device Type, U.K. Atrial Fibrillation Devices Market is fragmented into Diagnostic and Monitoring Devices and Therapeutic and Surgical Devices. The therapeutic and Surgical Devices segment dominates the market attributed to growing demands for ablation catheters for treating AF. This segment is also expected to witness the highest growth during the forecast period. Among the therapeutic and surgical devices, the Cardiac Rhythm Management Devices segment is the fastest-growing segment attributed to the increasing focus on early diagnosis.
The U.K. Atrial Fibrillation Devices Market is classified based on Disorder Type into Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation, Permanent Atrial Fibrillation, Others Atrial Fibrillation. The persistent Atrial Fibrillation segment accounted for the largest market share of the U.K. Atrial Fibrillation Devices market.
Market DynamicsGrowing Adoption Of Closure Devices
The rising number of patients suffering from atrial fibrillation (AF) in the U.K. is the major factor expected to propel the growth of the market. In addition, the rising cases are also resulting in increasing demand for left atrial appendage (LAA) closure devices to treat patients. The governments are taking initiatives to create awareness amongst people regarding the importance of left atrial appendage closure devices during the pandemic, which is the major factor expected to boost the market growth in 2020.
Increase In Prevalence Of Atrial Fibrillation In Geriatric Population
The increasing geriatric population with complications in the heart is the major factor driving the market. According to the Centers for Disease Control and Prevention (CDC), approximately 2 percent of people younger than 65 years old have AFib, while about 9 percent of people ages 65 and older have it.
High Cost of U.K. Atrial Fibrillation Devices
The high price factor will continue to hinder the atrial fibrillation devices' market value during the forecast timeframe and impede the adoption rates in underdeveloped and few developing countries.
Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis
U.K. Atrial Fibrillation Devices market is segmented based on regional analysis into four major regions: England, Northern Ireland, Scotland, and Wales. England is among the top revenue generator for atrial fibrillation devices. The high incidence rate of cardiovascular diseases in the region and development of the strong technologies in the country has witnessed significant growth for the product. The country also has a strong number of players present in the country across the atrial fibrillation value chain Another key country in the region is Northern Ireland, Scotland, and Wales. Focus on the improved treatment producers with implementation of the AI in Atrial fibrillations, supporting the product growth.
The market of AF devices is expected to witness healthy growth in 2022 post-COVID-19 outbreak. This can be attributed to increasing awareness among people about the importance of AF devices. This factor will boost the market growth in the forecast years. The rising number of patients suffering from atrial fibrillation (AF) and the growing geriatric population are the major factors expected to propel the growth of the market. In addition, the rising cases of COVID-19 are resulting in increasing demand for left atrial appendage (LAA) closure devices for treating the patients This is helping the market to witness progressive growth in the pandemic crisis.
| Report Attribute | Details |
| The market size value in 2021 | USD 706.1 million |
| The revenue forecast in 2031 | USD 2.063.9 million |
| Growth Rate | CAGR of 11.3% from 2021 to 2031 |
| The base year for estimation | 2020 |
| Quantitative units | Revenue in USD million and CAGR from 2021 to 2031 |
| Report coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments covered | Device Type, Disorder Type, End-User and Region |
| Regional scope | England, Northern Ireland, Scotland, and Wales |
| Key companies profiled | Abbott, Boston Scientific Corporation, Biotronik, Cardinal Health, GEHealthcare, Medtronic Plc, Siemens Healthineers AG, W. L. Gore & Associates, Inc., Hansen Medical Inc, Cardio focus, and Other Prominent Players |
The U.K. Atrial Fibrillation Devices Market size was estimated at USD 706.1 million and is expected to reach USD 2.063.9 million by 2031
Abbott, Boston Scientific Corporation, Biotronik, Cardinal Health, GEHealthcare, Medtronic Plc, Siemens Healthineers AG, W. L. Gore & Associates, Inc., Hansen Medical Inc, and Cardio focus and Other Prominent Players.
Therapeutic and Surgical Devices segment and Persistent Atrial Fibrillation segment
Drivers Growing Adoption Of Closure Devices
Atrial fibrillation (AF) is a type of cardiac arrhythmia which is caused by irregular electrical activities in the atria. It may occur with no symptoms but the most common ones associated with it are palpitations, fainting, congestive chest pain, or failure of the heart. The confirmation for AF is obtained by an electrocardiogram which exhibits an absence of the P wave and an irregular rate of ventricular contractions.
Select License Type
Select License Type
FATPOS CLIENT Appriciation DURING THE PROJECT
Working with Fatpos Global, allowed us to take advantage of their knowledge and easy approach, allowing us to collect important data utilizing a variety of techniques. The results were clearly presented and explained, and FG responded to our questions with speed and expertise.
|
Swiss-based global building materials manufacturer |
The analyses and presentations Fatpos Global have produced for us have been of a very high caliber and have allowed us to proactively improve our customer relationship management. They have also done so while maintaining complete anonymity. Without any doubt, we suggest Fatpos Global to you.
|
|
Tech-powered construction company |
We appreciate the team’s punctuality, flexibility in terms of report modification, post report purchase support and pleasant reaction all around. Overall, my experience with this company was nothing but positive, and I couldn't be more grateful for their excellent service. Thank you for all that you do!
|
|
American global management consulting firm |
We are able to concentrate on the topics and implications that are most important to our clients thanks to the adaptability and responsiveness of the team at Fatpos Global. We would highly recommend this company to anyone in need of their services, and I will certainly be using them again in the future.
|
|
Headquartered in Zug, Switzerland, leading supplier of medical and surgical instrument |
To better study our client demographics, develop the ideal product-price architecture, and enhance our target marketing initiatives, we hired Fatpos Global. Every component of the project was completed, and we are very happy with the useful insights and actionable results.
|
|
Kosovan company, A leading organic fertilizers producer |
Thank you for your team's generous assistance, The final report was delivered to me, and I find it to be really helpful. Also, you may be sure that I will get in touch with you if I ever require fresh materials for market research. Gratitude once more.
|
|
German specialty chemicals company based in Cologne, Germany |
